4576 - (株)デ・ウエスタン・セラピテクス研究所 2020/02/16〜

１年で辞任とかガースー無能やんけ

ドライヌさんこんばんにゃ☺

デ西のホームページからHｰ1129のパイプライン
削除されましたが、このままお蔵入りですか？
同時にわかもとの名前も無くなりましたが
復活はあると思いますか？

D. Western Therapeutics Institute , inc

ドラちゃん、唯一無二の投資先が、財団法人西洋療法研究所かよ
情けない

今日ほとんど誰も見てないから大きく恥晒す前にレス消しとけ
それみてこれも消しとくわ
それが身のためやで

>>556

これ何が凄いっめ翻訳アプリが凄い😄

>>543

財団法人西洋療法研究所
愛知 460-0003 JAPAN 名古屋市中区錦1-18-11
(翻訳)
米国食品医薬品局が承認した眼科手術補助薬"DW-1002"
2019年12月20日(現地時間) 米国食品医薬品局(FDA)は、D社が開発した内膜剥離指示用眼科補助薬であるDW-1002("BBG250")製品を承認した。 DWTIは、同製品のサブライセンシーであるオランダ眼科研究センター国際BV(以下"DORC")から承認の通知を受けた。
DW-1002 はすでに欧州などで DORC が製造·販売しています。
®
ILMBLUEという商号で活動する地域·国。米国では市場に出回る。
ティッシュブルーという商号で2020年4月のTM。 アメリカでの販売開始と同時に、DWTIへのロイヤリティ支払いが契約に基づいてアメリカでの販売に対して開始されます。 DORCは2019年10月にカナダで新薬申請を行い、DORCはさらなる海外展開を検討している。
この件については、DWTIは節目の支払いを受け取っておらず、DWTIの2019年12月期連結業績予想に変更はない見込みです。
DW-1002 について
BBG250は、九州大学の研究者が発明した眼科外科の補助剤の染色性能の高い染料であり、DW-1002はBBG250を主成分とする眼科外科の補助剤である。 DWTIは九州TLOからDW-1002の独占ライセンスを取得している。
DWTIはDORCに対し、日本を除く世界地域でDW-1002の独占サブライセンスを付与した。 DORCは、DWTIからサブライセンスを取得した後、実用化のための製剤の開発と本眼科用溶液の開発を完了した。 DORCは2010年9月から、ヨーロッパやその他の地域で本製品の製造と販売を行っています。
BBG250の高い染色性を利用し、眼内限膜の安全な染色を実現し、眼科手術時の膜剥離をサポートすることが期待されている。
日本では、DWTIが若本製薬(若本)に眼科用内限膜染色の独占サブライセンスを付与し、
2019年12月23日

白内障手術用の水晶体前包染色。 若本さんは、マーケティング承認を得るために開発を進めています。
DW-1002 製品の現状を次に示します。
開発コード
表示
市場
開発段階
進捗状況
DW-1002
白内障手術
ヨーロッパ·アメリカ·カナダ·ジャパン
日本
NDS の承認フェーズ III 調査の開始
フェーズIII研究
開始
D.O.R.C.Submission by D.によるマーケティングの準備中です。O.R.C. 若本で開発中
ワカモトで開発中

>>553

アホか。
資金力げ違うし、大人は幾ら損しても自分の金が減るわけではない。
ビクビクするはずがない。
アホか！

>>553

あんたつくづく面白いな
まともな日本語でお願いしたいわ

>>236910、December 23, 2019
( translation )

さて、なんでしょう？

>>550

材料があるから海外ネタだ。
今、上市に最も近く、どうなっているか？
がIR頼りしか解らないのが海外。

しかも海外は朝イチIR。

我々ホルダーではなく、一番ビビりながらから売って来てるのは、モルガン、野村だよ。

空売りを仕掛けてくるのはここが有望株で安くして現物を保有したい為。この先どうなるかは想像がつく。

しまいにはブラックロック！
オーホッホ❤️

出たー！
材料ないから海外！
ホルダーでも何か悲しい！
オーホッホ❤️

海外勢来るぞ❗️
準備しとけ❗️
これからだぞ❗️

仕掛けてくんな。海外勢✨✨

英語が得意な日本の方がいらっしゃるんですね！凄い！ご苦労様です！
オーホッホ❤️

>>545

　　ＤＷ-1002　復習

　わかもと製薬

　　　対象疾患　内境界膜染色　Ｐ3

　　　対象疾患　白内障手術　　Ｐ3

　欧州　　上市　　内境界膜剥離

　カナダ　申請　　内境界膜剥離

　米国　　承認　　内境界膜剥離

まさか海外の機関投資家が仕掛けてんのか❗️

http://pdf.irpocket.com/C4576/yUG5/boeO/fmzB.pdf

Our infrastructure technologies consist of three drug creation engines.

1.Compound Library

Our Compound Library is a unique library accumulated by the founder who has engaged in research and drug creation activities with a focus on inhibitors of protein kinases over a long term. Originally, the compounds were developed for the research purpose and included many highly active but at the same time equally toxic compounds, and some of representative ones are commercially available for research reagents.
Compounds in this library are called seed compounds from which drug candidate compounds are being created.

2.Drug Design

Our founder has engaged in development of drugs in partnership with Japanese pharmaceutical companies in the past. In addition to these findings, his enriched molecular pharmacological data and analytical capabilities originated from intracellular signal transduction research offer a big advantage for capabilities of designing new drugs or drug design capabilities in the fundamental research. These high drug design capabilities enable us to create drug candidate compounds at a high probability in the development of new drugs said to be one in ten to twenty thousand.

3.Drug-Western Method

The Drug-Western Method is a method to examine which protein an administered drug binds to in the body.
Under certain conditions the gene of a protein bound to the drug is isolated, and gene sequences are analyzed to identify which protein the drug bound to. By examining the function of the protein, the possibilities of the new drug to be developed can be elucidated.
Identifying the molecular target of a new drug at an early stage of the drug development not only clarifies the efficacy and safety of the drug but also has a great impact on the efficiency of subsequent new drug development including clinical studies.

Introduction

While general public’s understanding of the pharmaceutical industry may be that “drugs are manufactured and sold by pharmaceutical companies,” in recent years, the way of understanding is changing.

Today, in the United States which is running ahead of others in terms of pharmaceutical development, one from two newly marketed pharmaceuticals originates from the creation of “bio venture” companies.
The “bio venture” corresponds to the venture business specializing in pharmaceutical manufacture, which was first known in the United States in 2000. Considering that the presence of bio venture companies has now increased with a number of pharmaceuticals created by bio venture companies, we may safely say, “bio venture companies are playing the main role in drug design now; development of new pharmaceuticals would be difficult without bio venture companies.”

DWTI is one of such numerous, active bio venture companies. We wish to inform you what its features are among those.

The DWTI

D. Western Therapeutics Institute, Inc. (DWTI) is a bio venture company which is creating seeds of new pharmaceuticals with slogan of “Innovative New Drugs to the World from Japan.”

Features of DWTI

DWTI has three distinguished features as mentioned below:

No. 1: Specialized in basic studies

While the bio venture business covers a wide area, DWTI is specialized in the basic study, the very origin of pharmaceutical manufacturing.
Fully utilizing the original “engine” (fundamental technology) for manufacturing pharmaceuticals, which has been transferred from the corporate founder, DWTI is creating innovative pharmaceuticals never existing before.
As a consequence, DWTI is currently developing more than one development (“pipeline”) product with partner pharmaceutical manufacturers.

No. 2: Holding a marketed pharmaceutical

In December 2014, we saw the birth of the pharmaceutical launched in the market, the first one ever since our foundation. A bio venture company is considered to have high value if it holds a marketed product. We believe this proves our high level of technology and our enthusiasm for drug development for, in Japan, only a limited number of companies have so far succeeded in bringing the new pharmaceuticals created by them to the stage of marketing.
Furthermore, in addition to those articles whose basic study has been completed and which is being developed by the partner company, we have a number of articles which we are studying at our own laboratory. Although the probability of successful development of pharmaceuticals is extremely low, to hold a large number of development articles allows our business fundamentals to be stable.

No. 3: Development organization of a few people of superior ability

Another strength of DWTI is that it has a small-scale, high efficiency development organization.
Development of pharmaceuticals requires a large amount of funds and a long period, not excepting the basic studies.
Under such a circumstance, it is the DWTI’s development laboratory where highly skilled researchers with enthusiasm for pharmaceutical manufacturing are gathering.
Although the probability of succeeding in pharmaceutical development is extremely low, the DWTI’s enthusiasm for drug creation is leading the drug development to a success.

Supported by these features, DWTI will be able to continue making seeds of new pharmaceuticals, grow them and continue corporate growth while further improving the developed products.
With the mission of “Innovative New Drugs to the World from Japan,” we are targeting to become a leader in the industry.